President Biden declares COVID-19 pandemic is ‘over’

President Joe Biden said the COVID-19 “pandemic is over” during an interview with 60 Minutes

The remark comes at a time when the United States is averaging 391 new daily deaths from COVID-19. Cases and hospitalizations have been trending downward in the last few weeks, according to the latest data from the Centers for Disease Control and Prevention (CDC). Overall, more than 1 million Americans have died since the onset of the pandemic.

Despite the ongoing high caseload and number of deaths, Biden declared the pandemic over. 

“The pandemic is over,” Biden said during the interview, which aired Sept. 18. “We still have a problem with COVID. We’re still doing a lot of work on it. But the pandemic is over.”

Share prices of healthcare companies, including vaccine makers Moderna, Pfizer and BioNTech, dropped lower on Monday, according to Marketwatch

Biden’s interview also set off a wave of criticism from health leaders on Twitter.

“Is the pandemic over? … Not even close,” wrote Eric Feigl-Ding, epidemiologist and health economist. 

“There is a fine line between injecting a sense of optimism/hope and telling people the truth that with 400-500 deaths/day plus a very unpredictable winter ahead it’s far from over,” said Kavita Patel, MD, physician, health policy researcher and contributor for MSNBC.

Biden's comment also comes just weeks after the president contracted COVID-19.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.